Upcoming Events

Extraordinary times call for extraordinary events. And so, it’s our pleasure to invite you to an all-new, extraordinary Festival of Genomics and Biodata! Not only is the Festival the UK’s largest genomics event, it’s also become a place for the global genomics community to meet, learn and get inspired. Come and meet team Lifebit at Booth: 11B.

Firmly established as the leading Precision Medicine meeting in the Nordic region, since 2016 our conference has brought together the leading experts from government, industry, technology, research, and healthcare to share knowledge and connect. In 2023 these experts in the field of Precision Medicine will come together once more in Stockholm for the Nordic Precision Medicine Forum.

BioTechX Europe is Europe’s largest congress covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare. In 2023 our 3-day event will return to Basel, the pharma hub of Europe, this time with 2500 leaders in the field, 450 speakers and 100 start-ups all under one roof.
Past Events

BioData World Congress is Europe’s largest congress, discussing topics related to big data in pharma development and healthcare. Come meet our Chief Business Development Officer Thorben Seeger at booth 100 and learn more about how Lifebit is bringing precision medicine to life, through securely connecting researchers with the data they need to make tomorrow’s medicine more precise for patients.

On behalf of the Australasian Genomic Technologies Association (AGTA) conference organising committee and AGTA executive we warmly invite you to the 20th Annual AGTA Conference. This year marks the 20th anniversary for the association. With our first meeting held in Queensland’s Couran Cove in 2000, this year we return to Queensland’s beautiful Sunshine Coast for a special celebration.

We are excited to welcome you back in-person to Los Angeles for ASHG’s annual meeting, taking place this October 25-29. Attendees can look forward to reconnecting with peers, engaging in discussions on research findings and sessions, all while enjoying the beautiful attractions and backdrop LA has to offer for this long-awaited reunion. Come and meet team Lifebit at Booth #1034.

Working at the interface between biotechnology and technology – TechBio companies combine cutting-edge techniques from both sectors to draw insights from a wealth of data, including data concerning patients, drug molecules, healthcare infrastructure and research and development, to inform and transform drug discovery and patient care.

PPP’s Global Genomics Conference (GGC) will provide a platform for the exploration and discussion of some of the key policy and ethical considerations of participation in genomics and builds upon the more specific work that PPP has conducted and is conducting in the UK specifically and via our global genomics programmes of work.

The Bio-IT World Conference & Expo is the world’s premier event showcasing the technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. Chief Business Development Officer, Thorben Seeger, will be give Keynote Introduction.

The Pistoia Alliance’s annual spring conference will focus on Patient Centricity in R&D. Through a series of keynote presentations, focused discussions, and breakouts we will look at the challenges and opportunities for embedding patient centricity within the biopharma value chain—from early discovery right through to post commercialization and its potential for real-world data insights.

The panel is comprised of Greek health technology entrepreneurs at all stages, from early startup through global scale-up, located around the world. Among them will be Dr. Maria Chatzou Dunford, Founder & CEO at Lifebit.


Attending ViVE/HLTH in Miami? Round off your evenings with us (March 7 and 8) at the networking receptions held in the exhibit hall to learn more about our a patented technology that enables researchers to run analyses on multiple, distributed datasets in-situ and avoid risky movement of highly-sensitive data.